The Evaluation of Ga-68 MAA Distribution in Prostatic Artery Embolization Patients
试验速览
- 阶段
- 早期 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Ga-68 MAA radiotracer activity within adjacent organs
研究概览
简要总结
Purpose: The purpose of this study is to evaluate Ga-68 MAA distribution on PET/MRI after injection into the prostatic arteries in patients without prostate cancer who are being treated with prostate artery embolization for benign prostatic hyperplasia.
Participants: Study subjects will be 5 men scheduled to undergo the PAE procedure at UNC Hospital for benign prostatic hyperplasia.
Procedures (methods): Study subjects will undergo PAE using the standard technique. Prior to embolization of the prostatic artery with the bland embolic agent, Ga-68 MAA will be injected. Standard departmental radiation protection procedures will be followed. After the PAE procedure is complete, the patient will be transported to the UNC Biomedical Research Imaging Center to undergo PET/MRI.
详细描述
This study is an initial proof of concept evaluation to determine the feasibility of using Y-90 radioembolization performed using the Sniper balloon occlusion microcatheter to treat localized prostate cancer. This will be performed by evaluating Ga-68 MAA distribution on PET/MRI after injection into the prostatic arteries in patients without prostate cancer who are being treated with prostate artery embolization for benign prostatic hyperplasia. The distribution of the radiotracer activity within the prostate and any activity in adjacent organs will be determined for when the tracer is injected into the central prostatic arteries.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Age > 40
- •Prostate gland >50 grams as measured by pre-procedural CTA
- •Have previously taken BPH medication for 6 months without desired improvement of LUTS or has started medication and stopped due to unwanted side effects
- •Moderate to severe LUTS as defined by IPSS score >18
- •Peak urine flow rate (Qmax) <12 mL/sec
- •Capable of giving informed consent
- •Life expectancy greater than 1 year
排除标准
- •Severe vascular disease
- •Uncontrolled diabetes mellitus
- •Immunosuppression
- •Unable to lie flat, still or tolerate a PET/MRI scan.
- •Neurogenic bladder and/or sphincter abnormalities secondary to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes, etc.
- •Complete urinary retention
- •Impaired kidney function (serum creatinine level > 1.8 mg/dl or a glomerular filtration rate < 60 as approximated using serum creatinine levels) unless anuric and on dialysis.
- •Confirmed or suspected bladder cancer
- •Urethral strictures, bladder neck contracture, or other potentially confounding bladder pathology
- •Ongoing urogenital infection
- •Previous pelvic radiation or radical pelvic surgery
- •Confirmed or suspected malignancy of the prostate based on DRE, TRUS or PSA (> 10 ng/mL or > 4.0 ng/mL and < 10 ng/mL with free PSA < 25% of total PSA without a negative biopsy).
- •Uncorrectable coagulopathy including INR > 1.5 or platelets < 50,000
- •Contrast hypersensitivity refractory to standard medications (antihistamines, steroids)
研究组 & 干预措施
All participants
All enrolled study participants will receive Ga-68MAA and PET/MRI scan.
干预措施: Gallium 68 Macro-aggregated albumin (Drug)
结局指标
主要结局
Ga-68 MAA radiotracer activity within adjacent organs
时间窗: Upon completion of all study image data collection for all participants [approximately 1 year]
The mean radiotracer levels within adjacent organs in the target population of patients will be estimated in the sample of N=5 patients, along with standard errors, and 95% confidence intervals.
次要结局
- Ga-68 MAA radiotracer activity within the prostate gland(Upon completion of all study image data collection for all participants [approximately 1 year after study start])